Cargando…
Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities
BACKGROUND: European mistletoe (Viscum album) products used in cancer therapy are frequently combined with other anti-cancer-drugs. Hence, potential herb-drug interactions have become a major safety concern in mistletoe therapy. METHODS: Three European mistletoe products (Helixor® A, Helixor® M and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715639/ https://www.ncbi.nlm.nih.gov/pubmed/29202738 http://dx.doi.org/10.1186/s12906-017-2028-1 |
_version_ | 1783283806976868352 |
---|---|
author | Schink, Michael Dehus, Oliver |
author_facet | Schink, Michael Dehus, Oliver |
author_sort | Schink, Michael |
collection | PubMed |
description | BACKGROUND: European mistletoe (Viscum album) products used in cancer therapy are frequently combined with other anti-cancer-drugs. Hence, potential herb-drug interactions have become a major safety concern in mistletoe therapy. METHODS: Three European mistletoe products (Helixor® A, Helixor® M and Helixor® P from mistletoe grown on firs, apple trees and pines, respectively) were tested for inhibition of nine major cytochrome P450 (CYP) isoenzymes in a test system using pooled human liver microsomes and for induction of five CYP isoforms in human hepatocytes cultivated in vitro according to the relevant guideline. RESULTS: Major inhibition did not occur in any of the CYP marker reactions. For some CYP isoenzymes, a minor or intermediate inhibition could be observed, but without dose effect relationship. Induction activity (≥ 1.5-fold increase) was not found with any of the three mistletoe products. CONCLUSION: Since no induction capacity was found and major inhibition above 50% did not occur even with the highest concentration used, which is approximately 100,000-fold higher than the clinically relevant dose in plasma, a clinically relevant herb-drug interaction is not expected for Helixor® A, M, and P. |
format | Online Article Text |
id | pubmed-5715639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57156392017-12-08 Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities Schink, Michael Dehus, Oliver BMC Complement Altern Med Research Article BACKGROUND: European mistletoe (Viscum album) products used in cancer therapy are frequently combined with other anti-cancer-drugs. Hence, potential herb-drug interactions have become a major safety concern in mistletoe therapy. METHODS: Three European mistletoe products (Helixor® A, Helixor® M and Helixor® P from mistletoe grown on firs, apple trees and pines, respectively) were tested for inhibition of nine major cytochrome P450 (CYP) isoenzymes in a test system using pooled human liver microsomes and for induction of five CYP isoforms in human hepatocytes cultivated in vitro according to the relevant guideline. RESULTS: Major inhibition did not occur in any of the CYP marker reactions. For some CYP isoenzymes, a minor or intermediate inhibition could be observed, but without dose effect relationship. Induction activity (≥ 1.5-fold increase) was not found with any of the three mistletoe products. CONCLUSION: Since no induction capacity was found and major inhibition above 50% did not occur even with the highest concentration used, which is approximately 100,000-fold higher than the clinically relevant dose in plasma, a clinically relevant herb-drug interaction is not expected for Helixor® A, M, and P. BioMed Central 2017-12-04 /pmc/articles/PMC5715639/ /pubmed/29202738 http://dx.doi.org/10.1186/s12906-017-2028-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Schink, Michael Dehus, Oliver Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities |
title | Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities |
title_full | Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities |
title_fullStr | Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities |
title_full_unstemmed | Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities |
title_short | Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities |
title_sort | effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome p450 activities |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715639/ https://www.ncbi.nlm.nih.gov/pubmed/29202738 http://dx.doi.org/10.1186/s12906-017-2028-1 |
work_keys_str_mv | AT schinkmichael effectsofmistletoeproductsonpharmacokineticdrugturnoverbyinhibitionandinductionofcytochromep450activities AT dehusoliver effectsofmistletoeproductsonpharmacokineticdrugturnoverbyinhibitionandinductionofcytochromep450activities |